Approval · Notice of Compliance 28145 · 2022
ESOMEPRAZOLE: Notice of Compliance 28145
Issued May 12, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28145
- Date
- May 12, 2022
- Company
- Ethypharm IncMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph. To convert the product monograph to 2020 format
- Canadian reference product
- NEXIUM (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESOMEPRAZOLE | Not yet assigned | — |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM DIHYDRATE 20 MG per TAB
- ESOMEPRAZOLE MAGNESIUM DIHYDRATE 40 MG per TAB